Creeping Over the Chasm: Biotech's Perilous Managerial Transitions
Clinical challenges are tough enough; a new study shows that biotechs struggle with the basics of managerial transitions. With over 80% of companies reporting a significant organizational transformation-many because they've changed business models from discovery to development-the problem has major implications for strategies and for investors.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.